文献速递糖尿病

Index60作为1型糖尿病附加诊断标准

Index60 as an additional diagnostic criterion for type 1 diabetes.
PubMed 文献 · Diabetologia · 2021-01-26

在TrialNet Pathway to Prevention研究中,基线OGTT时2小时血糖≥11.1 mmol/l和/或Index60≥2.00的354例自身抗体阳性者被分为三组。仅Index60≥2.00组比仅血糖≥11.1 mmol/l组更年轻、C肽更低、多抗体阳性率更高,且4年糖尿病累积发病率达95%。

要点

  • Index60≥2.00可识别出血糖未达11.1 mmol/l但已具典型1型糖尿病特征者。
  • 仅Index60≥2.00组4年糖尿病累积发病率为95%(95%CI 86%,98%)。
  • 仅血糖≥11.1 mmol/l组年龄更大、C肽更高、超重/肥胖比例更高。

核心结论

  • 仅Index60≥2.00组比仅2小时血糖≥11.1 mmol/l组更具典型1型糖尿病特征,且诊断可能性相当。
  • 仅Index60≥2.00组在基线OGTT时未被识别,提示Index60可作为附加诊断标准。

研究设计与样本

  • 研究为TrialNet Pathway to Prevention研究中自身抗体阳性参与者的基线OGTT分析。
  • 共纳入354例,中位年龄11.2岁(范围1.7-46.6),49%男性,83%非西班牙裔白人。

主要发现

  • 仅血糖≥11.1 mmol/l组(n=76)、仅Index60≥2.00组(n=113)、两者均满足组(n=165)的平均年龄分别为22.9、11.8、14.7岁。
  • 三组早期(30-0分钟)C肽反应分别为1.0、0.50、0.43 nmol/l,AUC C肽分别为2.33、1.13、1.10 nmol/l。
  • 三组超重/肥胖比例分别为58%、16%、30%(所有比较p<0.0001),多抗体阳性比例分别为72%、92%、93%(p<0.001)。
  • 仅血糖≥11.1 mmol/l组和仅Index60≥2.00组的糖尿病进展率分别为61%(46/76)和63%(71/113)。
  • 仅Index60≥2.00组4年糖尿病累积发病率为95%(95%CI 86%,98%)。

关键数值与推荐

  • Index60≥2.00定义为复合血糖和C肽指标。
  • 2小时OGTT血糖≥11.1 mmol/l为Pathway to Prevention诊断标准,而Index60≥2.00不是。

临床怎么用

  • 在自身抗体阳性人群中,可考虑使用Index60≥2.00识别OGTT血糖未达诊断标准但已接近1型糖尿病诊断的个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to compare characteristics of individuals identified in the peri-diagnostic range by Index60 (composite glucose and C-peptide measure) ≥2.00, 2 h OGTT glucose ≥11.1 mmol/l, or both. METHODS: We studied autoantibody-positive participants in the Type 1 Diabetes TrialNet Pathway to Prevention study who, at their baseline OGTT, had 2 h blood glucose ≥11.1 mmol/l and/or Index60 ≥2.00 (n = 354, median age = 11.2 years, age range = 1.7-46.6; 49% male, 83% non-Hispanic White). Type 1 diabetes-relevant characteristics (e.g., age, C-peptide, autoantibodies, BMI) were compared among three mutually exclusive groups: 2 h glucose ≥11.1 mmol/l and Index60 <2.00 [Glu(+), n = 76], 2 h glucose <11.1 mmol/l and Index60 ≥2.00 [Ind(+), n = 113], or both 2 h glucose ≥11.1 mmol/l and Index60 ≥2.00 [Glu(+)/Ind(+), n = 165]. RESULTS: Participants in Glu(+), vs those in Ind(+) or Glu(+)/Ind(+), were older (mean ages = 22.9, 11.8 and 14.7 years, respectively), had higher early (30-0 min) C-peptide response (1.0, 0.50 and 0.43 nmol/l), higher AUC C-peptide (2.33, 1.13 and 1.10 nmol/l), higher percentage of overweight/obesity (58%, 16% and 30%) (all comparisons, p < 0.0001), and a lower percentage of multiple autoantibody positivity (72%, 92% and 93%) (p < 0.001). OGTT-stimulated C-peptide and glucose patterns of Glu(+) differed appreciably from Ind(+) and Glu(+)/Ind(+). Progression to diabetes occurred in 61% (46/76) of Glu(+) and 63% (71/113) of Ind(+). Even though Index60 ≥2.00 was not a Pathway to Prevention diagnostic criterion, Ind(+) had a 4 year cumulative diabetes incidence of 95% (95% CI 86%, 98%). CONCLUSIONS/INTERPRETATION: Participants in the Ind(+) group had more typical characteristics of type 1 diabetes than participants in the Glu(+) did and were as likely to be diagnosed. However, unlike Glu(+) participants, Ind(+) participants were not identified at the baseline OGTT.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Redondo MJ, Nathan BM, Jacobsen LM, et al. Index60 as an additional diagnostic criterion for type 1 diabetes. Diabetologia. 2021. PMID: 33496819. doi:10.1007/s00125-020-05365-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。